Abbott Laboratories
NYSE:ABT
Abbott Laboratories
Long-Term Debt
Abbott Laboratories
Long-Term Debt Peer Comparison
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbott Laboratories
NYSE:ABT
|
Long-Term Debt
$13.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
15%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Long-Term Debt
$14.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
14%
|
|
Boston Scientific Corp
NYSE:BSX
|
Long-Term Debt
$8.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Long-Term Debt
$597m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
Stryker Corp
NYSE:SYK
|
Long-Term Debt
$10.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
15%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Abbott Laboratories's Long-Term Debt?
Long-Term Debt
13.6B
USD
Based on the financial report for Mar 31, 2024, Abbott Laboratories's Long-Term Debt amounts to 13.6B USD.
What is Abbott Laboratories's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
15%
Over the last year, the Long-Term Debt growth was -7%. The average annual Long-Term Debt growth rates for Abbott Laboratories have been -8% over the past three years , -6% over the past five years , and 15% over the past ten years .